Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.

Welt, A., Marschner, N., Lerchenmueller, C., Decker, T., Steffens, C.-C., Koehler, A., Depenbusch, R., Busies, S., Hegewisch-Becker, S., 2016.

Breast Cancer Res Treat 156, 97–107. doi:10.1007/s10549-016-3727-x

Studie: CARIN; Indikation: Mammakarzinom; Jahr: 2016; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

iOMEDICO AG
Ellen-Gottlieb-Straße 19
79106 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com